United States securities and exchange commission logo





                             May 26, 2021

       Hugh Y. Rienhoff, Jr., M.D.
       Chief Executive Officer
       Imago BioSciences, Inc.
       329 Oyster Point Blvd., 3rd Floor
       South San Francisco, CA 94080

                                                        Re: Imago BioSciences,
Inc.
                                                            Amendment No. 1 to
Draft Registration Statement on Form S-1
                                                            Submitted May 19,
2021
                                                            CIK No. 0001623715

       Dear Dr. Rienhoff:

             We have reviewed your amended draft registration statement and
have the following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by providing the requested
information and either submitting
       an amended draft registration statement or publicly filing your
registration statement on
       EDGAR. If you do not believe our comments apply to your facts and
circumstances or do not
       believe an amendment is appropriate, please tell us why in your
response.

             After reviewing the information you provide in response to these
comments and your
       amended draft registration statement or filed registration statement, we
may have additional
       comments.

       Amendment No. 1 to Draft Registration Statement on Form S-1

       Bomedemstat in MF, page 3

   1.                                                   We note your response
to comment 7 and re-assert our comment. We do not believe that
                                                        your amended disclosure
that "there have been no dose-limiting toxicities or deaths related
                                                        to drug as of the
cut-off date" is properly balanced with your observation of eight serious
                                                        adverse events in this
trial that were deemed by investigators as possibly related to
                                                        bomedemstat. Please
disclose this observation in the summary section.
 Hugh Y. Rienhoff, Jr., M.D.
FirstName  LastNameHugh
Imago BioSciences, Inc. Y. Rienhoff, Jr., M.D.
Comapany
May        NameImago BioSciences, Inc.
     26, 2021
May 26,
Page 2 2021 Page 2
FirstName LastName
Intellectual Property, page 95

2.       We note your response to comment 12 and related amendments in your
filing. Please
         identify the specific foreign jurisdictions in which you have granted
patents or pending
         patent applications.
       You may contact Li Xiao at 202-551-4391 or Angela Connell at
202-551-3426 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Dillon Hagius at 202-551-7967 or Chris Edwards at 202-551-6761 with any
other
questions.



                                                              Sincerely,

                                                              Division of
Corporation Finance
                                                              Office of Life
Sciences
cc:      Benjamin A. Potter